Real-World Data Reveal Longer PFS With Elacestrant in Breast Cancer

Targeted Oncology 9 April 2025 by Seth Wander

Commentary | Video

At the American Society of Clinical Oncology Annual Meeting (ASCO) and the San Antonia Breast Cancer Conference, Wander and his fellow investigators presented real-world data of patients treated with elacestrant. The initial findings focused on clinical outcomes, such as treatment duration and therapy line usage. Early post-approval use skewed toward later lines, but Wander anticipates a shift toward second-line use as clinicians become more familiar with the drug.

In real-world studies, surrogates like time to next treatment or discontinuation are used to estimate progression-free survival (PFS). Wander acknowledges the lack of uniform scans, but despite these limitations, elacestrant performed well, with PFS estimates of 5 to 7 months. This exceeds those from the EMERALD trial (NCT03778931) at a median PFS of 2.8 months on the overall population. This suggests clinicians are selecting appropriate patients—those with ESR1 mutations who responded well to prior endocrine and CDK4/6 inhibitor therapy—optimizing real-world outcomes, according to Wander.

Link to full article and video : https://www.targetedonc.com/view/real-world-data-reveal-longer-pfs-with-elacestrant-in-breast-cancer